Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2022/09/22
First-half 2022 results Achievement of major milestones in the first half On track for a change of dimension
Read the release
2022/09/15
Interest for the ZENEO® auto-injector from an American pharmaceutical company
Read the release
2022/09/12
Safe, fast and effective use of ZENEO® Midazolam validated by a new human factors study in the United States
Read the release
2022/07/25
Great success of the exercise of warrants
Read the release
2022/07/25
ZENEO® Midazolam clinical study: completion of the injection phase
Read the release
2022/06/18
Agreement with BARDA on ZENEO® Midazolam
Read the release
2022/06/01
First injections of ZENEO® Midazolam for the clinical bioequivalence study
Read the release
2022/04/05
2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023
Read the release
2022/03/21
Conformity of the first industrial transposition batch of Zeneo® Hydrocortisone
Read the release
2021/12/17
Crossject strengthens its financial resources and gives all shareholders an interest in the 2022 outlook through a free allocation of equity warrants
Read the release
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Next page
Next ›
Last page
Last »
